Therapy Directory

Trastuzumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Trastuzumab as a study intervention. Browse Trastuzumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 12:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

678

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Metastatic Solid Tumor, Brain Metastases
Interventions: Trastuzumab emtansine, Tucatinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan, Valemetostat; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions: Trastuzumab Deruxtecan, Cisplatin, Carboplatin, Pembrolizumab, Pemetrexed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 123 Years
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Anchorage, Alaska • Los Alamitos, California • Los Angeles, California + 16 more

Conditions: Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Interventions: Trastuzumab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 12
States / cities: Duarte, California • Santa Rosa, California • Chicago, Illinois + 8 more

Conditions: Breast Cancer, Leptomeningeal Disease
Interventions: cDC1 Vaccine, Trastuzumab, Nivolumab; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Interventions: Tucatinib, Eribulin, Trastuzumab; Drug
Lead sponsor: Criterium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Albuquerque, New Mexico + 3 more

Conditions: Recurrent or Metastatic Solid Tumors
Interventions: Trastuzumab Deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Newport Beach, California • Atlanta, Georgia • Las Vegas, Nevada + 3 more

Conditions: HER2-positive Breast Cancer, Breast Cancer
Interventions: Paclitaxel, Trastuzumab, Pertuzumab, Pembrolizumab; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Albuquerque, New Mexico + 2 more

Conditions: Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
Interventions: OKI-219, Fulvestrant, Trastuzumab, Tucatinib, Atirmociclib, Ribociclib; Drug
Lead sponsor: OnKure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Encinitas, California • La Jolla, California • Los Angeles, California + 9 more

Conditions: Ovarian Cancer
Interventions: Trastuzumab Deruxtecan, Bevacizumab; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 32
States / cities: Burbank, California • La Jolla, California • Palo Alto, California + 25 more

Conditions: Breast Cancer, Neoplasm Metastasis
Interventions: Trastuzumab, RAD001; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
Interventions: Copper Cu 64-DOTA-Trastuzumab, Magnetic Resonance Imaging, Positron Emission Tomography, Trastuzumab, Trastuzumab Deruxtecan; Other · Procedure · Device + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

About this Trastuzumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Trastuzumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Trastuzumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Trastuzumab clinical trials

Filter and sort this therapy

Live official records

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

About this Trastuzumab clinical trials directory page